215 related articles for article (PubMed ID: 16919318)
1. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
Inan S; Cowan A
Pharmacol Biochem Behav; 2006 Sep; 85(1):39-43. PubMed ID: 16919318
[TBL] [Abstract][Full Text] [Related]
2. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
3. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride.
Umeuchi H; Kawashima Y; Aoki CA; Kurokawa T; Nakao K; Itoh M; Kikuchi K; Kato T; Okano K; Gershwin ME; Miyakawa H
Eur J Pharmacol; 2005 Aug; 518(2-3):133-9. PubMed ID: 16055114
[TBL] [Abstract][Full Text] [Related]
5. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Inan S; Dun NJ; Cowan A
Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
[TBL] [Abstract][Full Text] [Related]
7. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
8. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
9. Investigation of gastrin-releasing peptide as a mediator for 5'-guanidinonaltrindole-induced compulsive scratching in mice.
Inan S; Dun NJ; Cowan A
Peptides; 2011 Feb; 32(2):286-92. PubMed ID: 21126550
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
11. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
[TBL] [Abstract][Full Text] [Related]
12. Nalfurafine hydrochloride for the treatment of pruritus.
Inui S
Expert Opin Pharmacother; 2012 Jul; 13(10):1507-13. PubMed ID: 22663138
[TBL] [Abstract][Full Text] [Related]
13. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.
Umeuchi H; Togashi Y; Honda T; Nakao K; Okano K; Tanaka T; Nagase H
Eur J Pharmacol; 2003 Sep; 477(1):29-35. PubMed ID: 14512095
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a new kappa-opioid receptor agonist for the treatment of uremic pruritus.
Delmez JA
Nat Clin Pract Nephrol; 2006 Jul; 2(7):358-9. PubMed ID: 16932462
[No Abstract] [Full Text] [Related]
15. Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.
Inan S; Dun NJ; Cowan A
Molecules; 2021 Sep; 26(18):. PubMed ID: 34576988
[TBL] [Abstract][Full Text] [Related]
16. Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice.
Akiyama T; Carstens MI; Piecha D; Steppan S; Carstens E
Acta Derm Venereol; 2015 Feb; 95(2):147-50. PubMed ID: 24890341
[TBL] [Abstract][Full Text] [Related]
17. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
18. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
[TBL] [Abstract][Full Text] [Related]
19. Targeting Itch with Ligands Selective for κ Opioid Receptors.
Cowan A; Kehner GB; Inan S
Handb Exp Pharmacol; 2015; 226():291-314. PubMed ID: 25861786
[TBL] [Abstract][Full Text] [Related]
20. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates.
Ko MC; Husbands SM
J Pharmacol Exp Ther; 2009 Jan; 328(1):193-200. PubMed ID: 18842704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
